(Press-News.org) Embargoed for release until 5:00 p.m. ET on Monday 13 November 2023
Annals of Internal Medicine Tip Sheet
@Annalsofim
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------------------------
Virologic rebound observed in 20% of patients treated with nirmatrelvir-ritonavir
Abstract: https://www.acpjournals.org/doi/10.7326/M23-1756
Editorial: https://www.acpjournals.org/doi/10.7326/M23-2887
URL goes live when the embargo lifts
An observational study of patients being treated for acute COVID-19 in a multicenter health care system observed virologic rebound in about 20 percent of patients treated with nirmatrelvir-ritonavir (N-R) versus about 2 percent of those who did not receive treatment. The findings are published in Annals of Internal Medicine.
N-R is an oral antiviral widely used in the United Sates to reduce the incidence of hospitalization and death among individuals with mild to moderate COVID-19. Soon after its adoption into clinical care, a clinical and virologic rebound phenomenon was reported, but data are conflicting about how common it is.
Researchers from Massachusetts General Hospital and Brigham and Women’s Hospital studied 127 patients with acute COVID-19 to compare the frequency of virologic rebound in patients with (n=72) and without (n=55) N-R treatment. The study outcome was viral rebound within 3 weeks of an initial positive test, defined as either a positive SARS-CoV-2 viral culture following a prior negative culture or sustained elevated viral load after a prior decline. With frequent monitoring by both PCR and viral culture during the acute stages of COVID-19, the data showed that virologic rebound with replication-competent prolonged viral shedding occurred in approximately 1 in 5 individuals taking N-R. Only 1 untreated patient experienced virologic rebound. People who rebounded shedded live virus for a median of 14 days versus less than 5 dyas in those who did not. A regression model showed a trend towards higher rates of virologic rebound with earlier N-R initiation after the date of diagnosis and with earlier N-R initiation after the onset of symptoms. The researchers noted that compared with untreated individuals, those taking N-R were older, had received more COVID-19 vaccinations, and were more often immunosuppressed.
According to the study authors, these findings should be factored into consideration when weighing the benefits and risks of N-R treatment in patients at low risk for severe disease. Still, for patients at moderate to high-risk for severe COVID-19, the clinical benefits associated with N-R use are well established.
Media contacts: For an embargoed PDF or to speak to editorial author, Christina Wee, MD, MPH, please contact Angela Collom at acollom@acponline.org. To speak with the corresponding author, Mark J. Siedner, MD, MPH, please contact Haley Bridger at hbridger@mgb.org.
END
Virologic rebound observed in 20% of patients treated with nirmatrelvir-ritonavir
2023-11-13
ELSE PRESS RELEASES FROM THIS DATE:
One in five patients experience rebound COVID after taking Paxlovid, new study finds
2023-11-13
A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test—a phenomenon known as virologic rebound. By contrast, people not taking Paxlovid only experienced rebound about 2 percent of the time. Results are published in Annals of Internal Medicine.
“We conducted this study to address lingering questions about Paxlovid and virologic rebound in COVID-19 treatment,” said corresponding ...
Scientists discover key to a potential natural cancer treatment’s potency
2023-11-13
JUPITER, Fla. — Slumbering among thousands of bacterial strains in a collection of natural specimens at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, several fragile vials held something unexpected, and possibly very useful.
Writing in the journal Nature Chemical Biology, a team led by chemist Ben Shen, Ph.D., described discovery of two new enzymes, ones with uniquely useful properties that could help in the fight against human diseases including cancer. The discovery, published ...
Mount Sinai researchers find more than 4,700 gene clusters crucial for prognosis in 32 cancer types
2023-11-13
New York, NY (November 13, 2023)—Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different types of cancer. The study, published in Genome Research, serves as a comprehensive resource and lays the foundation for the development of next-generation cancer treatments and diagnostic markers.
Despite significant progress in cancer research, understanding the disease's genetic intricacies ...
Ammonia fuel offers great benefits but demands careful action
2023-11-13
Ammonia, a main component of many fertilizers, could play a key role in a carbon-free fuel system as a convenient way to transport and store clean hydrogen. The chemical, made of hydrogen and nitrogen (NH3), can also itself be burned as a zero-carbon fuel. However, new research led by Princeton University illustrates that even though it may not be a source of carbon pollution, ammonia’s widespread use in the energy sector could pose a grave risk to the nitrogen cycle and climate without proper engineering precautions.
Publishing their findings in PNAS, the interdisciplinary team of 12 researchers found that a well-engineered ammonia economy could help the world achieve ...
Low-intensity fires reduce wildfire risk by 60%, study finds
2023-11-13
November 13, 2023-- There is no longer any question of how to prevent high-intensity, often catastrophic, wildfires that have become increasingly frequent across the Western U.S., according to a new study by researchers at Columbia University Mailman School of Public Health and Stanford University. The analysis reveals that low-intensity burning, such as controlled or prescribed fires, managed wildfires, and tribal cultural burning, can dramatically reduce the risk of devastating fires for years at a time. The findings are some of the first to rigorously quantify the value of low-intensity fire and be released while Congress is reassessing ...
Astrophysicist uses NSF funding to grow the number of deaf, hard-of-hearing, and Hispanic researchers
2023-11-13
Astrophysicist Jason Nordhaus is breaking cultural and disciplinary boundaries by helping to grow the number of deaf, hard-of-hearing, and Hispanic researchers. And, in doing so, he is enabling these future scientists to drive discoveries in one of his areas of expertise—neutron star astrophysics.
Nordhaus, an associate professor of physics at Rochester Institute of Technology’s National Technical Institute for the Deaf, has earned a National Science Foundation grant that connects NTID with Texas Tech University, a Hispanic Serving Institution. Through a series of unique summer research exchanges ...
A ‘fish cartel’ for Africa could benefit the countries, and their seas
2023-11-13
Banding together to sell fishing rights could generate economic benefits for African countries, which receive far less from access to their fisheries on the global market than other countries do from theirs. By joining forces, UC Santa Barbara researchers say in a paper published in the journal Nature Communications, African fisheries would not just secure more competitive access fees, they could also protect their seas’ biodiversity.
“If African countries created a ‘fish cartel’ to sell fishing rights to foreign vessels, they could increase their fish biomass by 16% and make 23% more in profits,” ...
Absorbable scaffold outperforms angioplasty for lower-leg artery disease
2023-11-13
In patients with severe artery blockage in the lower leg, an artery-supporting device called a resorbable scaffold is superior to angioplasty, which has been the standard treatment, according to the results of a large international clinical trial co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.
Angioplasty involves the widening of a narrowed artery with a small, balloon-like mechanism. A resorbable scaffold is a stent-like structure that props the artery open but is biodegradable and dissolves within a few years, avoiding some of the potential complications of a permanent ...
New compound outperforms pain drug by indirectly targeting calcium channels
2023-11-13
A compound—one of 27 million screened in a library of potential new drugs—reversed four types of chronic pain in animal studies, according to new research led by NYU College of Dentistry’s Pain Research Center and published in the Proceedings of the National Academy of Sciences (PNAS).
The small molecule, which binds to an inner region of a calcium channel to indirectly regulate it, outperformed gabapentin without troublesome side effects, providing a promising candidate for treating pain.
Calcium channels play a central role in pain signaling, in part through the release of neurotransmitters such as glutamate and GABA— “the ...
This wireless, handheld, non-invasive device detects Alzheimer’s and Parkinson’s biomarkers
2023-11-13
An international team of researchers has developed a handheld, non-invasive device that can detect biomarkers for Alzheimer’s and Parkinson’s Diseases. The biosensor can also transmit the results wirelessly to a laptop or smartphone.
The team tested the device on in vitro samples from patients and showed that it is as accurate as the state of the art. Ultimately, researchers plan to test saliva and urine samples with the biosensor. The device could be modified to detect biomarkers for other conditions as well.
Researchers present their findings ...